EP0859761A4 - 4-azasteroides utilises pour le traitement d'etats hyperandrogeniques - Google Patents

4-azasteroides utilises pour le traitement d'etats hyperandrogeniques

Info

Publication number
EP0859761A4
EP0859761A4 EP96930822A EP96930822A EP0859761A4 EP 0859761 A4 EP0859761 A4 EP 0859761A4 EP 96930822 A EP96930822 A EP 96930822A EP 96930822 A EP96930822 A EP 96930822A EP 0859761 A4 EP0859761 A4 EP 0859761A4
Authority
EP
European Patent Office
Prior art keywords
azasteroides
treatment
hyperandrogenic conditions
hyperandrogenic
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP96930822A
Other languages
German (de)
English (en)
Other versions
EP0859761A1 (fr
Inventor
Raman K Bakshi
Soumya P Sahoo
Richard L Tolman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603487.1A external-priority patent/GB9603487D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0859761A1 publication Critical patent/EP0859761A1/fr
Publication of EP0859761A4 publication Critical patent/EP0859761A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
EP96930822A 1995-09-15 1996-09-11 4-azasteroides utilises pour le traitement d'etats hyperandrogeniques Ceased EP0859761A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US382695P 1995-09-15 1995-09-15
US3826 1995-09-15
GB9603487 1996-02-20
GBGB9603487.1A GB9603487D0 (en) 1996-02-20 1996-02-20 4-azasteroids for the treatment of hyperandrogenic conditions
PCT/US1996/014564 WO1997010217A1 (fr) 1995-09-15 1996-09-11 4-azasteroides utilises pour le traitement d'etats hyperandrogeniques

Publications (2)

Publication Number Publication Date
EP0859761A1 EP0859761A1 (fr) 1998-08-26
EP0859761A4 true EP0859761A4 (fr) 2000-01-26

Family

ID=26308763

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96930822A Ceased EP0859761A4 (fr) 1995-09-15 1996-09-11 4-azasteroides utilises pour le traitement d'etats hyperandrogeniques

Country Status (5)

Country Link
EP (1) EP0859761A4 (fr)
JP (1) JPH11512434A (fr)
AU (1) AU707324B2 (fr)
CA (1) CA2231041A1 (fr)
WO (1) WO1997010217A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6137399A (en) * 1998-09-09 2000-03-27 Merck & Co., Inc. Method of determining and reducing the risk of bph-related urologic events
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
JP4490689B2 (ja) * 2001-10-03 2010-06-30 メルク・シャープ・エンド・ドーム・コーポレイション アンドロゲン受容体調節剤としてのアンドロスタン１７β−カルボキサミド類
NZ534946A (en) * 2002-03-13 2007-05-31 Merck & Co Inc Fluorinated 4-azasteroid derivatives as androgen receptor modulators
US20040248957A1 (en) 2003-05-16 2004-12-09 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
AU2006229840B2 (en) * 2005-03-25 2010-12-23 Merck Sharp & Dohme Corp. Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
CN117801051A (zh) * 2022-09-30 2024-04-02 苏州德亘生物医药有限公司 一类eRF3a靶向蛋白降解机制治疗人类肿瘤的药物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007861A1 (fr) * 1992-10-06 1994-04-14 Merck & Co., Inc. 17β-CARBOXANILIDES DE 4-AZA-5α-ANDROSTAN-3-ONES UTILISES COMME INHIBITEURS DE 5α-REDUCTASE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US5151429A (en) * 1984-02-27 1992-09-29 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α reductase inhibitors
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
US5468860A (en) * 1992-11-19 1995-11-21 Merck & Co., Inc. New finasteride processes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007861A1 (fr) * 1992-10-06 1994-04-14 Merck & Co., Inc. 17β-CARBOXANILIDES DE 4-AZA-5α-ANDROSTAN-3-ONES UTILISES COMME INHIBITEURS DE 5α-REDUCTASE

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BAKSHI ET AL: "Erratum to J. Med. Chem. Vol 38, Nr 17, pages 3189-3192, 18 August 1995", JOURNAL OF MEDICINAL CHEMISTRY., vol. 39, no. 5, 1 March 1996 (1996-03-01), WASHINGTON US, pages 1192, XP002089558 *
BAKSHI R K ET AL: "4-Aza-3-oxo-5.alpha.-androst-1-ene-17.beta.-N-arylcarboxamides as Dual Inhibitors of Human Type 1 and Type 2 Steroid 5.alpha.-Reductases. Dramatic Effect of N-Aryl Substituents on Type 1 and Type 2 5.alpha.-Reductase Inhibitory Potency", JOURNAL OF MEDICINAL CHEMISTRY., vol. 38, no. 17, 18 August 1995 (1995-08-18), WASHINGTON US, XP002087243 *
CHEMICAL ABSTRACTS, vol. 122, no. 25, 19 June 1995, Columbus, Ohio, US; abstract no. 314919, ZHENG, JINHONG ET AL: "Synthesis of N-substituted-4-methyl-3-oxo-4-aza-5.alpha.-androstane- 17.beta.-carboxamide compounds" XP002121894 *
KURATA H ET AL: "SYNTHESIS AND TESTOSTERONE 5ALPHA-REDUCTASE-INHIBITORY ACTIVITY OF 4-AZA-5ALPHA-ANDROSTANE-17-CARBOXAMIDE COMPOUND WITH AN AROMATIC MOIETY IN THE C-17 CARBAMOYL GROUP", CHEMICAL AND PHARMACEUTICAL BULLETIN,JP,PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, vol. 44, no. 1, pages 115-121, XP000569266, ISSN: 0009-2363 *
MELLIN T N ET AL: "AZASTEROIDS AS INHIBITORS OF TESTOSTERONE 5ALPHA-REDUCTASE IN MAMMALIAN SKIN", JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 44, no. 2, February 1993 (1993-02-01), pages 121 - 131, XP002028037 *
RASMUSSON G H ET AL: "AZASTEROIDS AS INHIBITORS OF RAT PROSTATIC 5ALPHA-REDUCTASE", JOURNAL OF MEDICINAL CHEMISTRY, vol. 27, no. 12, December 1984 (1984-12-01), pages 1690 - 1701, XP002043194 *
See also references of WO9710217A1 *
ZHONGGUO YAOKE DAXUE XUEBAO (1995), 26(1), 1-4 *

Also Published As

Publication number Publication date
WO1997010217A1 (fr) 1997-03-20
EP0859761A1 (fr) 1998-08-26
JPH11512434A (ja) 1999-10-26
AU6973796A (en) 1997-04-01
CA2231041A1 (fr) 1997-03-20
AU707324B2 (en) 1999-07-08

Similar Documents

Publication Publication Date Title
EP0754042A4 (fr) Traitement de l'atherosclerose
FR2742331B1 (fr) Instrument pour l'execution d'une therapie endoscopique
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
EP0988265A4 (fr) Traitement d'aromatiques lourds
EP1014982A4 (fr) Composes de troglitazone pour le traitement de l'age critique
EP0810860A4 (fr) Procede et utilisation du radicicol pour le traitement de l'inflammation et de l'endotoxemie
NO961483D0 (no) Fremgangsmåte for behandling av oljeholdig formasjon
BE890648A (fr) Compositions pour le traitement de l'acne
FR2689215B1 (fr) Installation de traitement d'air.
DE69627414D1 (de) Zusammensetzung effektiv für die Entfernung von Asphalten
FR2771297B1 (fr) Sonde bicanaliculaire pour le traitement du larmoiement de l'oeil
EP0959879A4 (fr) Therapie photodynamique pour le traitement de l'arthrose
FR2705966B1 (fr) Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
EP0704571A3 (fr) Compositions pour le traitement textile
EP0761604A3 (fr) Agent pour le traitement des eaux
FR2746658B1 (fr) Valve de drainage implantable pour le traitement de l'hydrocephalie
FR2731885B1 (fr) Installation d'etageres demontables
FR2758465B1 (fr) Composition pour le traitement de l'amiante
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
IT1271567B (it) Procedimento per l'ulteriore trattamento di salcicce
MA23837A1 (fr) Benzamides pour le traitement de degenerescenses neurologiques
EP0800396A4 (fr) Traitement d'etats d'hyperandrogenie
FR2558372B1 (fr) Composition medicamenteuse pour le traitement de l'acne
NO973366D0 (no) Fremgangsmåte for behandling av multippel sklerose
NO982562D0 (no) Sammensetning for behandling av smerte

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980415

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991209

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20030117

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20041119